Steven C. Quay - 20 Jan 2026 Form 4/A - Amendment Insider Report for ATOSSA THERAPEUTICS, INC. (ATOS)

Role: President & CEO, Director
Signature: /s/ Steven C. Quay
Issuer symbol: ATOS
Transactions as of: 20 Jan 2026
Net transactions value: +$572,850
Form type: 4/A - Amendment
Filing time: 30 Jan 2026, 08:30:03 UTC
Date Of Original Report: 22 Jan 2026
Previous filing: 22 May 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
QUAY STEVEN C	President & CEO, Director	C/O ATOSSA THERAPEUTICS, INC.,, 1448 NW MARKET STREET, SUITE 500, SEATTLE	/s/ Steven C. Quay	30 Jan 2026	0001008227

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ATOS	Common Stock	Award	$0	+331,674	+2386%	$0.000000	345,572	20 Jan 2026	Direct	F1, F2
holding	ATOS	Common Stock						22,254	20 Jan 2026	By Ensisheim Partners, LLC	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ATOS	Stock Options (right to buy)	Award	$572,850	+950,000		$0.6030	950,000	20 Jan 2026	Common Stock	950,000	$0.6030	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the acquisition of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest one year from the Transaction Date.
F2	The original Form 4, filed on January 22, 2026, is being amended by this Form 4 amendment solely to correct an administrative error regarding the number of RSUs acquired.
F3	Ensisheim Partners, LLC ("Ensisheim") is wholly owned by the Reporting Person and Dr. Shu-Chih Chen. The Reporting Person and Dr. Chen share voting and investment power over the securities held by Ensisheim. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
F4	The options shall vest on a quarterly basis over 24 months following January 20, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. The options were issued on January 20, 2026, with an exercise price of $0.603, representing the closing stock price on January 20, 2026.